Liver Cancer

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

The Food and Drug Administration (FDA) approved Lenvima (lenvatinib) for the firstline treatment of patients with unresectable hepatocellular carcinoma (HCC).

A liver cancer specialist can be very beneficial for those diagnosed.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) for the treatment of previously treated patients with advanced hepatocellular carcinoma (HCC).

After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape.

Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar (sorafenib), according to phase 2 findings.

“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D.

People treated for liver cancer at an inner-city hospital experienced better survival odds if they had private health insurance, and also if they were married, according to the results of a recent study that considered how socioeconomic factors affect health outcomes for those with the disease.

The liver cancer treatment field has remained stagnant for years, but new agents are destined to enter the field in the near future, Ghassan K. Abou-Alfa, M.D., says.

Blue Faery, the Adrienne Wilson Liver Cancer Association, is a nonprofit corporation founded in 2002, with the intent to prevent, treat and cure primary liver cancer – particularly HCC – through research, education and advocacy. Its name, inspired by Adrienne, has a unique background.

A panel of international oncology experts recently met to exchange thoughts on developments in the field of hepatocellular carcinoma (HCC), the most common form of liver cancer. They discussed screening and staging issues, treatment of advanced HCC and results of recent clinical trials.

Can local and systemic therapies be combined to treat liver cancer?

Liver cancer diagnoses have increased in the past 25 years, but researchers are hopeful that they will start to drop.

For those with hepatitis B, taking an aspirin once a day could reduce the risk of getting liver cancer.